Compare VSECU & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSECU | ARDX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | 2014 |
| Metric | VSECU | ARDX |
|---|---|---|
| Price | $53.75 | $5.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 38.2K | ★ 4.8M |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.45 | $4.08 |
| 52 Week High | $68.10 | $8.40 |
| Indicator | VSECU | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 39.44 |
| Support Level | $44.69 | $4.89 |
| Resistance Level | $58.94 | $5.34 |
| Average True Range (ATR) | 3.58 | 0.31 |
| MACD | -0.42 | -0.02 |
| Stochastic Oscillator | 8.45 | 23.45 |
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.